SoftBank Group’s AbCellera Biologics ABCL Stock Holding History

SoftBank Group’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.2M	Hold	345,161	–	–	0.01%	28
2025 Q4	$1.18M	Buy	+345,161	New	+$1.54M	0.01%	30

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SoftBank Group's ABCL Position: Q1 2026 in Review

SoftBank Group held its AbCellera Biologics (ABCL) position steady in Q1 2026 at 345,161 shares worth $1.2M. The position accounts for 0.01% of the portfolio, ranked #28.

SoftBank Group first reported a position in ABCL in Q4 2025 and has held it in 2 quarters since. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

SoftBank Group held 345,161 shares of AbCellera Biologics worth $1.2M as of Q1 2026.
SoftBank Group left its AbCellera Biologics share count unchanged in Q1 2026.
AbCellera Biologics made up 0.01% of SoftBank Group's portfolio in Q1 2026, its #28 holding.
SoftBank Group first reported a position in AbCellera Biologics in Q4 2025 and has held it in 2 quarters since.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on SoftBank Group's 13F filing for Q1 2026, filed 15 May 2026.